- Home
- MDRR vs CLRB Comparison
MDRR vs CLRB Comparison
Compare MDRR & CLRB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | MDRR | CLRB |
|---|---|---|
| Founded | 2015 | 2002 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 12.8M | 12.9M |
| IPO Year | N/A | 2008 |
Fundamental Metrics
Financial Performance| Metric | MDRR | CLRB |
|---|---|---|
| Price | $11.56 | $3.10 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $10.00 |
| AVG Volume (30 Days) | 3.1K | ★ 44.3K |
| Earning Date | 11-06-2025 | 03-04-2026 |
| Dividend Yield | ★ 2.34% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $9.55 | $0.23 |
| 52 Week High | $14.52 | $10.19 |
Technical Indicators
Market Signals| Indicator | MDRR | CLRB |
|---|---|---|
| Relative Strength Index (RSI) | 48.34 | 47.93 |
| Support Level | $11.48 | $2.62 |
| Resistance Level | $12.49 | $3.60 |
| Average True Range (ATR) | 0.33 | 0.29 |
| MACD | 0.02 | 0.03 |
| Stochastic Oscillator | 41.08 | 54.60 |
Price Performance
Historical ComparisonAbout MDRR Medalist Diversified REIT Inc.
Medalist Diversified REIT Inc is engaged to acquire, reposition, renovate, lease, and manage income-producing properties with a focus on commercial properties, including flex-industrial and retail properties, multi-family residential properties, and hotel properties. The company operates as a UPREIT and owns properties through its subsidiary, Medalist Diversified Holdings, LP. Its reportable segments were retail center properties, flex center properties, and STNL properties.
About CLRB Cellectar Biosciences Inc.
Cellectar Biosciences Inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of drugs for the treatment of cancer. The company's core objective is to leverage a proprietary phospholipid drug conjugate (PDC) delivery platform to develop PDCs that are designed to specifically target cancer cells and deliver improved efficacy and safety as a result of fewer off-target effects. It has one operating and reportable segment focused on utilizing its PDC platform to develop drugs for the treatment of cancer.